74 Takebayashi K, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, et al. *Nat Med* 2001;**7**:961.
75 Zewail-Foote M, Ven-Shun L, Kohn H, Bearss D, Guzmán M, Hurley LH. *Chem Biol* 2001;**135**:1.
76 Herrero AB, Martín-Castellanos C, Marco E, Gago F, Moreno S. *Cancer Res* 2006;**66**:8155.
77 Erba E, Cavallaro E, Damia G, Mantovani R, Di Silvio A, Di Francesco AM, et al. *Oncol Res* 2005;**14**:579.
78 García-Nieto R, Manzanares I, Cuevas C, Gago F. *J Am Chem Soc* 2000;**122**:7172.
79 Bonfanti M, La Valle E, Fernández-Sousa J-M, Faircloth G, Caretti G, Mantovani R, et al. *Anticancer Drug Des* 1999;**14**:179.
80 García-Nieto R, Manzanares I, Cuevas C, Gago F. *J Med Chem* 2000;**43**:4367.
81 García-Rocha M, García-Grávalos MD, Ávila J. *Br J Cancer* 1996;**73**:875.
82 Takebayashi K, Pourquier P, Yoshida A, Kohlhagen G, Pommier Y. *Proc Natl Acad Sci U S A* 1999;**96**:7196.
83 Leal JFM, Martínez-Díez M, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, et al. *Br J Pharmacol* 2010;**161**:1099.
84 Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, et al. *Clin Cancer Res* 2014;**20**:2205.
85 http://www.mskcc.org/cancer-care/trial/13-170.
86 Martínez EJ, Owa T, Schreiber SL, Corey EJ. *Proc Natl Acad Sci U S A* 1999;**96**:3496.
87 Martínez EJ, Corey EJ, Owa T. *Chem Biol* 2001;**8**:1151.
88 Leal JFM, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, et al. *Biochem Pharmacol* 2009;**78**:162.
89 http://www.pharmamar.com/zalypsis-fase-ii.aspx.
90 McGovren JP, Clarke GL, Pratt EA, DeKoning TF. *J Antibiot* 1984;**37**:63.
91 (a) Boger DL. *Pure Appl Chem* 1994;**66**:837; (b) Boger DL, Johnson DS. *Proc Natl Acad Sci U S A* 1996;**92**:3642; (c) Boger DL, Boyce CW, Garbaccio RM, Golberg JA. *Chem Rev* 1997;**97**:787.
92 Cacciari B, Romagnoli R, Baraldi PG, Da Ros T, Spalluto G. *Expert Opin Ther Patents* 2000;**10**:1853.
93 Li LH, DeKoning TF, Kelly RC, Krueger WC, McGovern JP, Padbury GE, et al. *Cancer Res* 1992;**52**:4904.
94 Ogasawara H, Nishio K, Takeda Y, Ohmori T, Kubota N, Funayama Y, et al. *Jpn J Cancer Res* 1994;**85**:418.
95 Schwartz GH, Patnaik A, Hammond LA, Rizzo J, Berg K, von Hoff DD, et al. *Ann Oncol* 2003;**14**:775.
96 Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, et al. *Am J Clin Oncol* 2002;**25**:308.
97 Baraldi PG, Tabrizi MA, Preti D, Fruttarolo F, Avitabile B, Bovero A, et al. *Pure Appl Chem* 2003;**75**:187.
98 Shavit E. *Fungi* 2008;**1**:18.
99 Neels JF, Gong J, Yu X, Sturla SJ. *Chem Res Toxicol* 2007;**20**:1513.
100 For a review of pyrrolobenzodiazepines as sequence-selective DNA binding agents, see Kamal A, Reddy MK, Srivastava AK, Srikanth YVV. In: Ekinci D, editor. *Medicinal chemistry and drug design*. Rijeka, Croatia: InTech; 2012.
101 Kopka ML, Goodsell DS, Baikalov I, Grzeskowiak K, Cascio D, Dickerson RE. *Biochemistry* 1994;**33**:13593.